Dublin, Ireland
Dublin, Ireland

Time filter

Source Type

Moccia M.,Stephens College | Cortigiani M.,Stephens College | Monasterolo C.,Stephens College | Torri F.,Stephens College | And 4 more authors.
Organic Process Research and Development | Year: 2015

Herein is reported the development of a new process to manufacture (S)-pregabalin. The method comprises six steps, run under the catalysis of a recyclable polymer bound phase transfer catalyst, and afforded (S)-pregabalin in overall 54% yield, starting from building blocks acetylacetone, isovaleraldehyde, and nitromethane. © 2015 American Chemical Society.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2015 | Award Amount: 774.00K | Year: 2016

The aim of this project is to bring together subject matter experts from the academic and non-academic sectors to develop three new categories of quaternary ammonium salts to be used as catalysts for the cost-efficient and green manufacture of high value active pharmaceutical ingredients. In order to achieve this objective the proposal brings together 3 partners with complementary skills: University of Naples(UNIN): experts in the preparation and purification of cyclic peptides. Experts in solid phase synthesis and immobilisation of peptides on solid support. KelAda Pharmachem: Phase transfer catalysis/organo catalysis/scale-up of chemical processes University of Linz(JKU Linz): experts in design of new ammonium salts and optimisation of enantioselective phase transfer catalyses. We have broken this proposal into the following separate Work Packages: WP1. Preparation of new designer ammonium salts [WP leader: Kelada] WP2. Preparation of cyclic peptide based ammonium salts [WP leader: UNINA] WP3. Evaluation of new ammonium salt catalysts prepared through WP1 [WP JKULinz] WP4. Evaluation of new Ammonium salt catalysts prepared through WP2[WP leader: UNINA] WP5. Application of Ammonium salts to drug production [WP leader: Kelada] WP6. Scale up of key steps or the manufacture of drugs [WP leader: Kelada] WP 7. Management, Communication & Dissemination [WP leader: KelAda] The above WPs will be undertaken via a series of interlinked secondment of researchers between consortium partners and will be complemented by a series of training and other initiatives to facilitate interdisciplinary and intersectoral knowledge sharing and exchange.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2014 | Award Amount: 234.00K | Year: 2015

The aim of this project is to bring together subject matter experts from the academic and non-academic sectors to develop a platform of green chemoenzymatic methods for the production of high value active pharmaceutical ingredients both those currently on the market, and those in development pipelines of the Pharma industry. The partners will exemplify the use of the platform through its application in the production of 4 drugs currently on the market namely Duloxetine, Atomexetine, Ramosetron and Paricalcitol. In order to achieve this objective the proposal brings together 3 partners with complementary skills: Kelada Pharmachem: Phase transfer catalysis/organo catalysis/scale-up of chemical processes Cerbios Pharma: Biocatalysis and fermentation methodologies for drug production IC-CNR: Protein crystallography and enzymatic engineering


KelAda Pharmachem | Entity website

ServicesOur services are centred on the provision of contract synthesis and process development. In particular wefocus upon reducing costs of production by avoiding expensive transition metals thus impacting economics and long term sustainability ...


KelAda Pharmachem | Entity website

We are actively engaged in the development of ground-breaking processes for the manufacture of high value generic or soon-to-be generic drugs. These novel processes confer significant cost advantages to the manufacturer - typically 70-80% savings on raw materials costs ...


KelAda Pharmachem | Entity website

KelAda Pharmachem was established in Ireland to acquire and develop intellectual assets in the pharmachemical space. The companys model is to in-license and develop novel chemistry into scalable processes which can then be out-licensed to major pharmaceutical players ...


KelAda Pharmachem | Entity website

Currently AvailableProductsWe leverage our proprietary technology and processes to offer a range of niche products for usein the synthesis ofdrugs currentlyin clinical development or for use as medicinal chemistry templates.Click here to view our catalogue of productsPlease contact us for orders and enquiries


KelAda Pharmachem | Entity website

Currently Available Licenses KelAda Pharmachem is actively seeking licensees to our proprietary manufacturing process for Pregabalin. The key features of the process are as follows: Estimated cost of materials (ton scale) ca ...

Loading KelAda Pharmachem collaborators
Loading KelAda Pharmachem collaborators